A Phase 2 interventional study of AZD5718 and AZD5718 in Coronary Artery Disease, sponsored by AstraZeneca. Completed at 9 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-06-30.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Coronary Artery Disease by AstraZeneca — 1 open to participants now, 1 under way, none of them phase 3. Coronary Artery Disease · AstraZeneca.
Among the 25 studies in Coronary Artery Disease by AstraZeneca, this one is the 9th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2017, is one of 5 in phase 2, and was the 19th registered.
4,864 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.
Browse Coronary Artery Disease studies →1 of the 25 studies in Coronary Artery Disease by AstraZeneca is open now, in 4 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Denmark, France and 1 more country
Ages 12–130
By country, each count listing its studies:
Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 129 is close to the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 76 across the 22 interventional studies, 10,568 across the 3 observational. Of the 24 that completed or were terminated, 11 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Coronary Artery Disease by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, single-blind, placebo-controlled, parallel-group, multicentre study in patients with CAD. The study will be conducted at approximately 10 centres in 3 countries. Approximately 138 CAD patients will be randomized to AZD5718 or placebo (treatment duration 12 weeks).
This is a randomized, single-blind, placebo-controlled, parallel-group, multicentre study in patients with CAD. The study will be conducted at approximately 10 centres in 3 countries (Denmark, Finland and Sweden).
Patients suitable for the study will be identified and screened for eligibility after being hospitalized for Acute Coronary Syndrome (ACS) (Visit 1) comprising ST Elevation Myocardial Infarction (STEMI) or Non-ST Elevation Myocardial Infarction (non-STEMI). At Visit 1, after signing informed consent, study measurements will take place at days 1, 2, 3 and 5 post ACS, where feasible. It is planned that approximately 138 CAD patients will be randomized to ensure at least 66 evaluable patients receiving AZD5718 Dose B or placebo are included with 12 weeks treatment. For supporting dose selection in future studies, a treatment arm with 28 randomized patients receiving AZD5718 Dose A is included in the study. The study was originally designed to be a 4-week study and was amended to be a 12-week study. Therefore, the total number of patients is greater than required for a 12 weeks study (about 100), since some patients will only have 4 weeks of treatment.
An evaluable patient is defined as a patient with a valid Coronary Flow Velocity Reserve (CFVR) measurement at Visit 2 and one post baseline visit as judged by the CFVR Core lab.
On Day 1 (Visit 2), 7 to 28 days after the ACS event, patients willing to participate in the study will complete the screening procedure and, if eligible, be randomized. Treatment duration will be 12 weeks. During the treatment phase, patients will come in to the clinic for study measurements at 2 weeks (visit 3), 4 weeks (visit 4), 8 weeks (visit 4b) and 12 weeks (visit 4c).
A follow-up visit (Visit 5) will be performed at 4 weeks (±4 days) after last dose in order to ensure safety and well-being of the patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
ACS 7-28 days prior to study randomization (ACS defined as STEMI, non STEMI event documented by (ECG), cardiac enzymes [troponin] and angiogram) Provision of signed and dated, written prior to any study specific procedures
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AZD5718 Dose A once daily
Drug: AZD5718
AZD5718 Dose B once daily
Drug: AZD5718
Matching placebo once daily
Drug: Placebo
Change From Baseline in Creatinine-normalized u-LTE4 at Week 4
Creatinine-normalized u-LTE4 is calculated as uLTE4/creatinine
Time frame: Baseline and 4 weeks
Change From Baseline in Creatinine-normalized u-LTE4 at Week 12
Creatinine-normalized u-LTE4 is calculated as uLTE4/creatinine
Time frame: Baseline and 12 weeks
Change From Baseline in CFVR at Week 12
CFVR = Coronary Flow Velocity Reserve = LAD(hyperaemic)/LAD(rest)
Time frame: Baseline and 12 weeks
Change From Baseline in CFVR at Week 4
CFVR = Coronary Flow Velocity Reserve = LAD(hyperaemic)/LAD(rest)
Time frame: Baseline and 4 weeks
Summary of Plasma Concentrations of AZD5718
Time frame: 16 weeks
Change From Baseline in LAD Hypereamic Flow at 4 Weeks
LAD=Left Anterior Descending
Time frame: Baseline and 4 weeks
Change From Baseline in LVEF at 4 Weeks
LVEF=Left Ventricular Ejection Fraction
Time frame: Baseline and 4 weeks
Change From Baseline in LV Longitudinal Early Diastolic Strain Rate at 4 Weeks
LV=Left Ventricular
Time frame: Baseline and 4 weeks
Change From Baseline in LV-GLS at Rest at Week 4
LV-GLS = Left Ventricular Global Longitudinal Strain
Time frame: Baseline and 4 weeks
Change From Baseline in LV-GCS at Rest at Week 4
LV-GCS = Left Ventricular Global Circumferential Strain
Time frame: Baseline and 4 weeks
Change From Baseline in LAD Resting Mean Diastolic Flow Velocity at 4 Weeks
LAD=Left Anterior Descending
Time frame: Baseline and 4 weeks
The study was conducted in 3 countries at 9 sites; 3 in Denmark, 2 in Finland and 4 in Sweden.
| Milestone | AZD5718 (200 mg) | AZD5718 (50 mg) | Placebo |
|---|---|---|---|
| Started | 52 | 25 | 52 |
| Completed | 50 | 24 | 51 |
| Not completed | 2 | 1 | 1 |
Creatinine-normalized u-LTE4 is calculated as uLTE4/creatinine
| Ratio | AZD5718 (200 mg) | AZD5718 (50 mg) | Placebo |
|---|---|---|---|
| Change From Baseline in Creatinine-normalized u-LTE4 at Week 4 | 0.04 ± 92.55 | 0.09 ± 84.32 | 1.09 ± 44.38 |
Creatinine-normalized u-LTE4 is calculated as uLTE4/creatinine
| Ratio | AZD5718 (200 mg) | AZD5718 (50 mg) | Placebo |
|---|---|---|---|
| Change From Baseline in Creatinine-normalized u-LTE4 at Week 12 | 0.04 ± 92.55 | 0.09 ± 84.32 | 1.09 ± 44.38 |
CFVR = Coronary Flow Velocity Reserve = LAD(hyperaemic)/LAD(rest)
| Ratio | AZD5718 (200 mg) | AZD5718 (50 mg) | Placebo |
|---|---|---|---|
| Change From Baseline in CFVR at Week 12 | 0.93 ± 23.64 | 0.98 ± 39.53 | 1.16 ± 33.46 |
CFVR = Coronary Flow Velocity Reserve = LAD(hyperaemic)/LAD(rest)
| Ratio | AZD5718 (200 mg) | AZD5718 (50 mg) | Placebo |
|---|---|---|---|
| Change From Baseline in CFVR at Week 4 | 1.03 ± 28.34 | 1.15 ± 31.47 | 1.08 ± 33.16 |
| nmol/L | AZD5718 (200 mg) | AZD5718 (50 mg) |
|---|---|---|
| Baseline: 1-8 Hours Post-Dose | 611.88 ± 234.50 | 47.88 ± 497.86 |
| 2 weeks (Visit 3): 20-28 Hours Post-Dose | 59.36 ± 90.97 | 16.57 ± 127.80 |
| 4 weeks (Visit 4): Pre-Dose | 48.00 ± 68.17 | 11.01 ± 60.70 |
| 4 weeks (Visit 4): 0-2 Hours Post-Dose | 339.28 ± 243.04 | 38.68 ± 159.56 |
| 4 weeks (Visit 4): 2-4 Hours Post-Dose | 919.22 ± 51.26 | 148.64 ± 71.86 |
| 4 weeks (Visit 4): 4-8 Hours Post-Dose | 649.09 ± 49.89 | 105.40 ± 52.16 |
| 12 weeks (Visit 4c): Pre-Dose | 65.39 ± 91.52 | 13.97 ± 88.12 |
| 16 weeks (Visit 5) - FUP 1 month | 0.51 ± 16.39 | 0.50 ± 0.00 |
LAD=Left Anterior Descending
| m/sec | AZD5718 (200 mg) | AZD5718 (50 mg) | Placebo |
|---|---|---|---|
| Change From Baseline in LAD Hypereamic Flow at 4 Weeks | 0.02 ± 0.16 | 0.04 ± 0.16 | 0.03 ± 0.17 |
LVEF=Left Ventricular Ejection Fraction
| percent LVEF | AZD5718 (200 mg) | AZD5718 (50 mg) | Placebo |
|---|---|---|---|
| Change From Baseline in LVEF at 4 Weeks | -0.23 ± 5.30 | 2.70 ± 6.39 | 0.48 ± 5.00 |
LV=Left Ventricular
| 1/s | AZD5718 (200 mg) | AZD5718 (50 mg) | Placebo |
|---|---|---|---|
| Change From Baseline in LV Longitudinal Early Diastolic Strain Rate at 4 Weeks | 1.02 ± 30.61 | 0.98 ± 33.55 | 1.03 ± 30.45 |
LV-GLS = Left Ventricular Global Longitudinal Strain
| Percent LV-GLS | AZD5718 (200 mg) | AZD5718 (50 mg) | Placebo |
|---|---|---|---|
| Change From Baseline in LV-GLS at Rest at Week 4 | -0.41 ± 3.00 | 0.34 ± 2.47 | -0.63 ± 2.61 |
LV-GCS = Left Ventricular Global Circumferential Strain
| Percent | AZD5718 (200 mg) | AZD5718 (50 mg) | Placebo |
|---|---|---|---|
| Change From Baseline in LV-GCS at Rest at Week 4 | 0.34 ± 7.24 | 1.71 ± 5.40 | -1.88 ± 6.78 |
LAD=Left Anterior Descending
| m/sec | AZD5718 (200 mg) | AZD5718 (50 mg) | Placebo |
|---|---|---|---|
| Change From Baseline in LAD Resting Mean Diastolic Flow Velocity at 4 Weeks | 1.01 ± 23.31 | 0.92 ± 23.68 | 0.99 ± 20.14 |
Collected over Treatment period, up to 12 weeks. Non-serious events are listed at a 0.03% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AZD5718 (200 mg) | 0/52 (0%) | 4/52 (7.7%) | 27/52 (51.9%) |
| AZD5718 (50 mg) | 0/25 (0%) | 3/25 (12%) | 12/25 (48%) |
| Placebo | 0/51 (0%) | 4/51 (7.8%) | 22/51 (43.1%) |
| Event | AZD5718 (200 mg) | AZD5718 (50 mg) | Placebo |
|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/52 | 1/25 | 0/51 |
| Angina pectorisCardiac disorders | 0/52 | 1/25 | 0/51 |
| Ventricular fibrillationCardiac disorders | 0/52 | 1/25 | 0/51 |
| Pancreatitis acuteGastrointestinal disorders | 0/52 | 1/25 | 0/51 |
| Non-cardiac chest painGeneral disorders | 0/52 | 1/25 | 0/51 |
| Chest painGeneral disorders | 2/52 | 0/25 | 1/51 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/52 | 0/25 | 1/51 |
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 0/52 | 0/25 | 1/51 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/52 | 0/25 | 1/51 |
| Post procedural sepsisInfections and infestations | 1/52 | 0/25 | 0/51 |
| Event | AZD5718 (200 mg) | AZD5718 (50 mg) | Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 6/52 | 4/25 | 7/51 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/52 | 4/25 | 7/51 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/52 | 0/25 | 1/51 |
| DizzinessNervous system disorders | 5/52 | 2/25 | 4/51 |
| DiarrhoeaGastrointestinal disorders | 2/52 | 1/25 | 4/51 |
| Alanine aminotransferase increasedInvestigations | 0/52 | 0/25 | 4/51 |
| AnaemiaBlood and lymphatic system disorders | 4/52 | 0/25 | 2/51 |
| Chest painGeneral disorders | 3/52 | 1/25 | 3/51 |
| FatigueGeneral disorders | 3/52 | 1/25 | 0/51 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/52 | 0/25 | 1/51 |
| Age, Continuous(Years) | AZD5718 (200 mg) | AZD5718 (50 mg) | Placebo | Total |
|---|---|---|---|---|
| Mean | 61.9 ± 8.21 | 61.4 ± 8.12 | 61.1 ± 8.51 | 61.5 ± 8.26 |
| Sex: Female, Male(Participants) | AZD5718 (200 mg) | AZD5718 (50 mg) | Placebo | Total |
|---|---|---|---|---|
| Female | 7 | 0 | 10 | 17 |
| Male | 45 | 25 | 41 | 111 |
| Ethnicity (NIH/OMB)(Participants) | AZD5718 (200 mg) | AZD5718 (50 mg) | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 51 | 25 | 51 | 127 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | AZD5718 (200 mg) | AZD5718 (50 mg) | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 |
| White | 52 | 25 | 50 | 127 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Oct 2017 to primary completion in Apr 2020, 29 months.
Results were first posted in Jun 2021, 1 year 2 months after primary completion.
Of 26 industry-sponsored phase 2 interventional studies under Coronary Artery Disease, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 29. This study's 29 months is above that.
Counting every sponsor, half of 55 studies reached it within 28 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD5718